title: Dismal long-term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?
authors: Keith
authors: K
authors: Sibson
authors: Colin
authors: C
authors: Steward
authors: John
authors: J
authors: Moppett
authors: Jacqueline
authors: J
authors: Cornish
authors: Nick
authors: N
authors: Goulden
mesh_terms: D000293:Adolescent; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D019008:Drug Resistance, Neoplasm; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D033581:Stem Cell Transplantation
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab